고형암 (전체) · CLDN18.2

6개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved6 programs
AntibodyCurated CoreFDAAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

CAR-CLDN18.2 T-Cells (CAR-CLDN18.2 T-Cells)

Advanced Solid Tumor · CLDN18.2

#CLDN182#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen University General Hos…Preclinical

Claudin18.2 CAR-T cells (Claudin18.2 CAR-T cells)

Advanced Pancreatic Carcinoma; Advanced Gastric Carcinoma · Advanced Pancreatic Carcinoma

#AdvancedPancreaticCarcinoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleEssen BiotechPhase 2

Mesothelin and Claudin 18.2 CAR-T cells (Mesothelin and Claudin 18.2 CAR-T cells)

Pancreatic Cancer; Pancreatic Carcinoma · Pancreatic Cancer

#PancreaticCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting